An update to rosacea treatment guidelines provides a comprehensive summary of management options, including expert evaluations–based on the phenotypes of each patient–to serve as a guide for tailoring treatment and care.
FMX103 1.5%, a novel topical minocycline foam, proves to be a respectable choice for treatment of moderate to severe papulopustular rosacea.
Compelling evidence supports IVM 1% cream as an effective topical treatment for papulopustular rosacea, that improves QoL over time.
Topical treatment with benzyl benzoate and crotamiton may be an effective treatment for rosacea and demodicosis, indirectly supporting a key role of the mite in the pathophysiology of rosacea.
Effects on self-perception and emotional, social, and overall well-being were significantly greater in patients with severe erythema of rosacea.
In the skin microbiota of patients with rosacea, specific bacterial taxa were significantly enriched or depleted, with variations noted across age, sex, disease extent, and subtype of rosacea.
Superficial needle-scraping can be a useful alternative or addition to standardized skin surface biopsy for evaluation of Demodex-associated facial papulopustular eruptions.
FMX103 is a topical foam formulation of the antibiotic minocycline.
Vasoconstrictors oxymetazoline and brimonidine achieve significant success in improving erythema in patients with rosacea.
Vascular endothelial growth factor may be a new target for future rosacea treatment.